The coronavirus shots target an omicron variant named XBB.1.5. That specific strain is no longer dominant but it’s close enough to coronavirus strains causing most COVID-19 illnesses today that FDA determined it would offer good cross-protection.

Thursday, the Food and Drug Administration's scientific advisers reviewed whether the next round of shots in the U.S. should only include protection against the newest variants that are now dominant worldwide — a branch of the omicron family tree named XBB.